Jump to content

Quifenadine

From Wikipedia, the free encyclopedia
Quifenadine
Clinical data
Trade namesFenkarol
Other names3-Quinuclidinyldiphenylmethanol
Routes of
administration
Oral (tablets), IM injection
ATC code
Legal status
Legal status
  • OTC (tablets), Rx-only (solution for IM injection) (RU)
Pharmacokinetic data
Bioavailability45% (Tmax = 1 hour)[1]
MetabolismLiver
Identifiers
  • 1-Azabicyclo[2.2.2]octan-3-yl(diphenyl)methanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23NO
Molar mass293.410 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)(c2ccccc2)C4C3CCN(CC3)C4
  • InChI=1S/C20H23NO/c22-20(17-7-3-1-4-8-17,18-9-5-2-6-10-18)19-15-21-13-11-16(19)12-14-21/h1-10,16,19,22H,11-15H2
  • Key:PZMAHNDJABQWGS-UHFFFAOYSA-N

Quifenadine (Russian: хифенадин, trade name: Fenkarol, Фенкарол) is a 2nd generation antihistamine drug, marketed mainly in post-Soviet countries.[2][3] Chemically, it is a quinuclidine derivative.[citation needed]

The drug has antiarrhythmic properties,[medical citation needed] probably due to the presence of a quinuclidine nucleus in the molecule's core. It acts as a calcium channel blocker and influences the activity of potassium channels.[clarification needed] In children with cardiac arrhythmia, combination therapy with quifenadone and either amiodarone or propafenone was found to be more effective than monotherapy with either amiodarone or propafenone.[non-primary source needed][4]

Quifenadine is a derivative of quinuclidylcarbinol, which reduces the effects of histamine on organs and systems.[citation needed] Quifenadine is a competitive blocker of H1 receptors.[medical citation needed]

According to manufacturers’ package leaflet, quifenadine reduces tissue histamine levels by activating diamine oxidase, an enzyme that inactivates histamine.[5][6] According to the precise claims done by manufacturers, quifenadine's ability to reduces the histamine content in tissues is related to its ability to activate diamine oxidase.[5][6] This statement on whether quifenadine activates diamine oxidaase has not been evaluated or approved by any regulatory authority, and have not been proved by any placebo-controlled study or any peer-reviewed medical journal publication.

The antihistaminic qualities of quifenadine are associated with the presence of a cyclic quinuclidine core in the structure and the distance between the diphenylcarbinol group and the nitrogen atom.[medical citation needed] In terms of antihistaminic activity and duration of action, quifenadine is superior to diphenhydramine.[medical citation needed] Quifenadine reduces the toxic effect of histamine, eliminates or weakens its bronchoconstrictor effect and spasmodic effect on the smooth muscles of the intestines, has a moderate antiserotonin and weak cholinolytic effect, has well-defined antipruritic and desensitizing properties.[medical citation needed] Quifenadine weakens the hypotensive effect of histamine and its effect on capillary permeability, does not directly affect cardiac activity and blood pressure, does not have a protective effect in aconitine arrhythmias.[medical citation needed][7]

Indications

[edit]

Synthesis

[edit]

Same precursor as for mequitazine. Use patent:[8]

Synthesis:[9] Patent:[10] Prec:[11][12]

The Grignard reaction between methylquinuclidine-3-carboxylate [38206-86-9] (1) and phenylmagnesium bromide (2) gave the benzhydryl alcohol product ~29% yield. The ethyl ester is cas: [6238-33-1]

See also

[edit]

References

[edit]
  1. 1 2 "Fencarol (quifenadine) Tablets, for Oral Use. Full Prescribing Information". State Register of Medicines (in Russian). Retrieved 4 January 2016.
  2. ↑ "Quifenadine". Drugs.com. Retrieved 28 January 2014.
  3. ↑ Makarov L, Balykova L, Soldatova O, Komolyatova V, Serebruany V (2010). "The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial". American Journal of Therapeutics. 17 (4): 396–401. doi:10.1097/MJT.0b013e3181a86987. PMID 19487925. S2CID 43654011.
  4. ↑ Soldatova ON, Balykova LA, Makarov LM, Komolyatova VN, Chuprova SN, Soldatov OM, Kornilova TI (2008-09-01). "Эффективность Фенкарола В Сочетании С Традиционными Противоаритмическими Средствами При Экстрасистолии У Детей" [Effectiveness of Fencarol in Combination With Traditional Anti-Arithmic Medicines in Children With Extrasystole]. RUDN Journal of Medicine (in Russian) (3): 46–51. ISSN 2313-0245. Archived from the original on 20 November 2020. Retrieved 18 November 2020.
  5. 1 2 "Фенкарол — инструкция по применению, дозы, побочные действия, аналоги, описание препарата: таблетки,раствор для внутримышечного введения, 10 мг/мл, 25 мг".
  6. 1 2 "Фенкарол инструкция по применению: показания, противопоказания, побочное действие – описание Phencarol таблетки 50 мг: 15 или 30 шт. (43436) - справочник препаратов и лекарств".
  7. ↑ "Quifenadine". compendium.com.ua. Retrieved 24 July 2022.
  8. ↑ Mikhail Davydovich Mashkovsky, et al. U.S. patent 4,117,139 (1978).
  9. ↑ Kaminka, M. É., Mikhlina, E. E., Vorob’eva, V. Ya., Yanina, A. D., Komarova, N. A., Mashkovskii, M. D., Yakhontov, L. N. (June 1976). "Synthesis and study of a new antihistamine preparation fenkarol". Pharmaceutical Chemistry Journal. 10 (6): 748–752. doi:10.1007/BF00758500.
  10. ↑ Micail Emmanuilovic Kaminka, DE 2502916 (1975 to VSESOJUZNYJ NAUCNO-ISSLEDOVATEL'SKIJ CHIMIKO-FARMACEVTICESKIJ INSTITUT IMENI SERGO ORDZONIKIDZE MOSKAU/MOSKVA SU).
  11. ↑ , U.S. patent 2,901,486 (1959).
  12. ↑ Harry J. Wadsworth, et al. U.S. patent 5,091,397 (1992 to Beecham Group PLC).